Obesity endangers the lives of millions of people worldwide, through comorbidities such as heart disease, cancers, type 2 diabetes, stroke, arthritis, and major depression. New approaches to control body weight remain a high priority. Vaccines traditionally have been used to protect against infectious diseases and, more recently, for unconventional targets such as drug addiction. Methodologies that could specifically modulate the bioavailability of an endogenous molecule that regulates energy balance might provide a new foundation for treating obesity. Here we show that active vaccination of mature rats with ghrelin immunoconjugates decreases feed efficiency, relative adiposity, and body weight gain in relation to the immune response elicited against ghrelin in its active, acylated form. Three active vaccines based on the 28-aa residue sequence of ghrelin, a gastric endocrine hormone, were used to immunize adult male Wistar rats (n ؍ 17). Synthetic ghrelin analogs were prepared that spanned residues 1-10 [ghrelin (1-10) Ser-3(butanoyl) hapten, Ghr1], 13-28 [ghrelin (13-28) hapten, Ghr2], and 1-28 [ghrelin(1-28) Ser-3(butanoyl) hapten, Ghr3], and included n-butanoyl esters at Ser-3. Groups immunized with Ghr1 or Ghr3 showed greater and more selective plasma binding capacity for the active, Ser-3-(n-octanoyl) form of ghrelin as compared with Ghr2 or keyhole limpet hemocyanin vaccinated controls. Accordingly, they gained less body weight, with sparing of lean mass and preferential reduction of body fat, consistent with reduced circulating leptin levels. The ratio of brain͞serum ghrelin levels was lower in rats with strong anti-ghrelin immune responses. Effects were not attributable to nonspecific inflammatory responses. Vaccination against the endogenous hormone ghrelin can slow weight gain in rats by decreasing feed efficiency.feed efficiency ͉ ghrelin ͉ obesity ͉ body weight regulation ͉ vaccine A pproximately 1 billion people worldwide are overweight or obese (body mass index ϭ 25-29.9 or Ն30 kg͞m 2 , respectively), with disproportionately higher prevalence rates in affluent countries (1). For example, in the United States, the National Health and Nutrition Examination Survey (NHANES) found that, in [2003][2004], Ϸ66% of all American adults 20 years of age or older were overweight or obese. Almost 4 of every 5 adult men aged 40-59 were so classified (2). Even in children and adolescents between the ages of 6-11 and 12-19, 19% and 17%, respectively, were overweight (2). Alarmingly, the prevalence of obesity has tripled for adolescents in the past two decades. The increase in the number of people who are overweight or obese cuts across all ages, racial and ethnic groups, and both genders (2), and is increasingly global (3, 4). For example, the prevalence of obesity in urban preschoolers in China climbed Ͼ8-fold between 1989 and 1997 (5), and the rate of obesity in British adults rose almost 3-fold from 1980-2002 (6). In 2000, Ͼ110,000 deaths in the United States were associated with obesity, as shown by confound...